sur SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma Holds Successful Annual General Meeting
SCHOTT Pharma conducted its virtual Annual General Meeting on February 4, 2025, achieving unanimous approval for all agenda items. This includes the appointment of Dr. Wolfram Carius to the Supervisory Board, replacing Dr. Wolfgang Wienand.
SCHOTT Pharma exceeded its 2024 fiscal targets, highlighting profitable growth and promotion to the MDAX. Shareholders engaged with the management, discussing growth prospects and market challenges for 2025.
The meeting approved a dividend of EUR 0.16 per share, reflecting confidence in the company's trajectory. KPMG was elected as the new auditor. Around 97% of share capital was represented, with high approval for proposed agenda items.
CEO Andreas Reisse emphasized SCHOTT Pharma's focus on innovation and strategic growth, while CFO Dr. Almuth Steinkühler confirmed the commitment to shareholder returns amid market challenges.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SCHOTT Pharma AG & Co. KGaA